Literature DB >> 16875916

Evaluation of AMPD1 C34T genotype as a predictor of mortality in heart failure and post-myocardial infarction patients.

Richard P Collins1, Barry R Palmer, Anna P Pilbrow, Chris M Frampton, Richard W Troughton, Tim G Yandle, Lorraine Skelton, A Mark Richards, Vicky A Cameron.   

Abstract

BACKGROUND: The AMPD1 gene C34T polymorphism has previously been associated with prolonged survival in small cohorts of heart failure (HF) and coronary artery disease patients. This study aimed to corroborate the association of the AMPD1 C34T polymorphism with survival in larger myocardial infarction (MI) and HF cohorts.
METHODS: Genotypes were obtained for 935 post-MI (PMI) and 433 patients with established HF, with median follow-up times of 5.4 and 3.1 years, respectively. At admission, cardiac function was assessed by nuclear ventriculography (PMI) and echocardiography (HF) and plasma cardiac neurohormones were assayed.
RESULTS: Differences in mortality by AMPD1 genotype did not achieve significance, either for the overall HF (P = .07) or the overall PMI group (P = .28), but AMPD1 genotype predicted mortality in patients of both cohorts with a history of MI (HxMI). In contrast to previous studies, the mutant T allele was associated with poorer outcome. Mortality in HF HxMI patients was significantly different between genotype groups (n = 144, mortality CC 56.5%, CT/TT 77.8%, P = .027), but not in patients without HxMI. In PMI patients, the association of genotype with survival in the HxMI subgroup trended toward significance (n = 147, mortality CC 29.8%, CT/TT 45.5%, P = .093). Multivariate analysis of combined PMI and HF cohorts showed that HxMI patients with CT/TT genotype were at greater risk than all other groups (P < .001).
CONCLUSION: This study suggests that AMPD1 C34T genotype is not a predictor of survival in heart disease patients, except possibly those with HxMI.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16875916     DOI: 10.1016/j.ahj.2005.12.015

Source DB:  PubMed          Journal:  Am Heart J        ISSN: 0002-8703            Impact factor:   4.749


  9 in total

1.  Genetic variants are not associated with outcome in patients with coronary artery disease and left ventricular dysfunction: results of the Genetic Substudy of the Surgical Treatment for Ischemic Heart Failure (STICH) trials.

Authors:  Arthur M Feldman; Lilin She; Dennis M McNamara; Douglas L Mann; Michael R Bristow; Alan S Maisel; Daniel R Wagner; Bert Andersson; Luigi Chiariello; Christopher S Hayward; Paul Hendry; John D Parker; Normand Racine; Craig H Selzman; Michele Senni; Janina Stepinska; Marian Zembala; Jean Rouleau; Eric J Velazquez; Kerry L Lee
Journal:  Cardiology       Date:  2015-01-13       Impact factor: 1.869

Review 2.  Genetic prediction of heart failure incidence, prognosis and beta-blocker response.

Authors:  Fabiana Filigheddu
Journal:  Mol Diagn Ther       Date:  2013-08       Impact factor: 4.074

3.  AMPD1 gene mutations are associated with obesity and diabetes in Polish patients with cardiovascular diseases.

Authors:  Krzysztof Safranow; Janina Suchy; Katarzyna Jakubowska; Maria Olszewska; Agnieszka Bińczak-Kuleta; Grzegorz Kurzawski; Ryszard Rzeuski; Edyta Czyżycka; Beata Łoniewska; Zdzisława Kornacewicz-Jach; Andrzej Ciechanowicz; Dariusz Chlubek
Journal:  J Appl Genet       Date:  2010-11-25       Impact factor: 3.240

4.  Shortage of Cellular ATP as a Cause of Diseases and Strategies to Enhance ATP.

Authors:  Todd A Johnson; H A Jinnah; Naoyuki Kamatani
Journal:  Front Pharmacol       Date:  2019-02-19       Impact factor: 5.810

5.  The common G-866A polymorphism of the UCP2 gene and survival in diabetic patients following myocardial infarction.

Authors:  Barry R Palmer; Courtney L Devereaux; Sukhbir S Dhamrait; Tessa J Mocatta; Anna P Pilbrow; Chris M Frampton; Lorraine Skelton; Tim G Yandle; Christine C Winterbourn; A Mark Richards; Hugh E Montgomery; Vicky A Cameron
Journal:  Cardiovasc Diabetol       Date:  2009-06-15       Impact factor: 9.951

6.  Myocardial infarction in a patient with left ventricular noncompaction: a case report.

Authors:  Mehrnoush Toufan; Roya Shahvalizadeh; Majid Khalili
Journal:  Int J Gen Med       Date:  2012-08-06

Review 7.  AMP deaminase 1 gene polymorphism and heart disease-a genetic association that highlights new treatment.

Authors:  Ryszard T Smolenski; Iwona Rybakowska; Jacek Turyn; Paweł Romaszko; Magdalena Zabielska; Anne Taegtmeyer; Ewa M Słomińska; Krystian K Kaletha; Paul J R Barton
Journal:  Cardiovasc Drugs Ther       Date:  2014-04       Impact factor: 3.727

Review 8.  Genetic polymorphisms associated with heart failure: A literature review.

Authors:  Mengqi Guo; Guanlun Guo; Xiaoping Ji
Journal:  J Int Med Res       Date:  2016-01-14       Impact factor: 1.671

Review 9.  Effects of AMPD1 gene C34T polymorphism on cardiac index, blood pressure and prognosis in patients with cardiovascular diseases: a meta-analysis.

Authors:  Ai-Fang Feng; Zhong-Hui Liu; Shu-Long Zhou; Shi-Yuan Zhao; Yan-Xin Zhu; Huai-Xin Wang
Journal:  BMC Cardiovasc Disord       Date:  2017-07-03       Impact factor: 2.298

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.